Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$94.1M in Q4 2024 → $41.7M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Actuate Therapeutics Inc | 36.9% | Unchanged | 10,049,996 | $15.4M |
| Opus Genetics Inc | 36.3% | Unchanged | 3,683,429 | $15.1M |
| Cognition Therapeutics Inc | 16.6% | Unchanged | 6,000,000 | $6.9M |
| Rein Therapeutics Inc | 7.4% | Added 50% | 2,982,375 | $3.1M |
| Lantern Pharma Inc | 2.5% | Trimmed 71% | 249,397 | $1.04M |
| In8bio Inc | 0.3% | Trimmed 52% | 80,957 | $114K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lantern Pharma Inc | Trimmed | −615,038 | −$2.56M | 2.5% |
| Rein Therapeutics Inc | Added | +1,000,000 | +$1.04M | 7.4% |
| In8bio Inc | Trimmed | −86,848 | −$122K | 0.3% |
quarter ended March 31, 2026 · filed May 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rein Therapeutics Inc | Added | +291,624 | +$379K | 4.9% |
| Lantern Pharma Inc | Trimmed | −145,072 | −$199K | 2.2% |
| In8bio Inc | Trimmed | −85,612 | −$127K | 0.5% |
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| In8bio Inc | Exited | −286,664 | −$622K | — |
| In8bio Inc | New | +253,417 | +$593K | 0.7% |
| Lantern Pharma Inc | Trimmed | −6,208 | −$18.8K | 3.7% |
quarter ended September 30, 2025 · filed November 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Actuate Therapeutics Inc | Added | +84,917 | +$568K | 75.6% |
| Lantern Pharma Inc | Trimmed | −60,237 | −$262K | 5.0% |
quarter ended June 30, 2025 · filed August 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| In8bio Inc | Trimmed | −8,313,337 | −$17.4M | 0.8% |
| Opus Genetics Inc | Added | +2,688,180 | +$2.53M | 4.8% |
| Actuate Therapeutics Inc | Added | +71,428 | +$436K | 83.9% |
| Lantern Pharma Inc | Trimmed | −131,757 | −$416K | 4.7% |
quarter ended March 31, 2025 · filed May 14, 2025
No position changes this quarter.
Loading...
